CORONA Remedies Share Price
2106.70-21.10 (-0.99%)
+46.46% past 1 Year
Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas. Its diversified product
Corporate filings & documents
Announcements
Intimation of participation in Analyst / Investor Conference
2 weeks agoIntimation of participation in Analyst / Investor Conference
2 weeks agoTranscript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30 2026
3 weeks agoTranscript of Earnings Call with Analyst / Investor on Unaudited Financial Results for the first quarter and three months ended June 30 2026
3 weeks agoIntimation for Schedule of Analysts / Investor Conference
3 weeks agoIntimation for Schedule of Analysts / Investor Conference
3 weeks agoAudio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors
1 month agoAudio Recording of Q1 FY27 Earnings Conference Call with Analysts / Investors
1 month agoNewspaper Publication of Unaudited Financial Results for the first quarter and three months ended June 30 2026
1 month agoNewspaper Publication of Unaudited Financial Results for the first quarter and three months ended June 30 2026
1 month agoAnalyst/Investor presentation
1 month agoAnalyst/Investor presentation
1 month agoPress Release on Financial Results for Q1FY27
1 month agoPress Release on Financial Results for Q1FY27
1 month agoUnaudited Financial Results for the first quarter and three months ended June 30 2026
1 month agoUnaudited Financial Results for the first quarter and three months ended June 30 2026
1 month agoOutcome of Board Meeting
1 month agoOutcome of Board Meeting
1 month agoIntimation for Schedule of Analysts / Investor Conference
1 month agoIntimation for Schedule of Analysts / Investor Conference
1 month agoCorona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 inter alia to consider and approve Unaudited Financial Results on Standalone and Consolidated Basis for First Quarter and Three Months ended June 30 2026
1 month agoCorona Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 inter alia to consider and approve Unaudited Financial Results on Standalone and Consolidated Basis for First Quarter and Three Months ended June 30 2026
1 month agoDeclaration of Voting Results and Scrutinizers Report for 22nd Annual General Meeting
1 month agoDeclaration of Voting Results and Scrutinizers Report for 22nd Annual General Meeting
1 month agoOutcome of 22nd Annual General Meeting
1 month agoOutcome of 22nd Annual General Meeting
1 month agoCertificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the first quarter ended June 30 2026
1 month agoCertificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the first quarter ended June 30 2026
1 month agoPress Release for Commencement of Commercial Production
2 months agoPress Release for Commencement of Commercial Production
2 months agoIntimation under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015-Commencement of Commercial Production
2 months agoIntimation under Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015-Commencement of Commercial Production
2 months agoIntimation of Closure of Trading Window for dealing in securities of CORONA Remedies Limited in terms of SEBI (Prohibition of Insider Trading) Regulations 2015
2 months agoIntimation of Closure of Trading Window for dealing in securities of CORONA Remedies Limited in terms of SEBI (Prohibition of Insider Trading) Regulations 2015
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sepia Investments Ltd & Others
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sepia Investments Ltd & Others
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sepia Investments Ltd & Others
2 months agoThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sepia Investments Ltd & Others
2 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund
2 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund
2 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund
2 months agoThe Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Invesco Mutual Fund
2 months agoNewspaper Publication - Notice of 22nd Annual General Meeting Intimation of Record Date and E-voting information
2 months agoNewspaper Publication - Notice of 22nd Annual General Meeting Intimation of Record Date and E-voting information
2 months agoAnnual Report 2025-26
2 months agoCommunication to Shareholders - Annual Report 2025-26
2 months agoCommunication to Shareholders - Annual Report 2025-26
2 months agoBusiness Responsibility and Sustainability Reporting for the F.Y. 2025-26
2 months agoBusiness Responsibility and Sustainability Reporting for the F.Y. 2025-26
2 months agoAnnual Report for the F.Y. 2025-26
2 months agoAnnual reports
No annual reports found
Concalls & investor presentations
Aug 2026
ConcallPresentation
Jul 2026
ConcallPresentation
May 2026
ConcallPresentation
May 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Feb 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-06-19
Dividend
10.0
Company details
Registered office
C – Mondeal Business Park Near Gurudwara, S. G. Highway Thaltej Ahmedabad Gujarat PIN: 380059 Tel No: 079 4023 3000 Fax No: NULL Email: [email protected] Internet: www.coronaremedies.com
Registrars
Office No S6-2, 6th Floor, Pinnacle Business Park,ext to Ahura Centre, Mahakali Caves Road, Andheri (East) Mumbai - 400093(old address - Bharat Tin Works building, 1st floor, Opp. Vasant Oasis, Andheri East Mumbai - 400 059Tel: + 91 21 626 38200Fax: Office No S6-2, 6th Floor, Pinnacle Business Park Next to Ahura Centre, Mahakali Caves Road Andheri (E) PIN: Tel No: 91-022-62638200 Fax No: 91-022-62638299 Email: [email protected]
Management
Chetna Dharajiya, Company Secretary & Compliance Officer
Kirti Mehta, Chairman
Nirav Mehta, Managing Director & Chief Executive Officer
Ankur Mehta, Joint Managing Director
Ameet Desai, Non Executive Independent Director
Monica Kanuga, Non Executive Independent Director
Bhaskar Iyer, Non Executive Independent Director
Viral Sitwala, Whole Time Director
Shirish Belapure, Non Executive Independent Director
Details
BSE 544644
NSE CORONA
ISIN INE02ZQ01018